High-Resolution PET-CT Imaging for Surgical Margin Visualization
Not Applicable
Not yet recruiting
- Conditions
- CancerSolid Malignant Tumors
- First Posted Date
- 2025-04-08
- Last Posted Date
- 2025-04-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 50
- Registration Number
- NCT06915454
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment with HER2-targeted Therapy
Early Phase 1
Not yet recruiting
- Conditions
- Locally Advanced CancerMetastatic Cancer
- Interventions
- Drug: ABY-025 Loading DoseDrug: [68Ga]Ga-ABY-025
- First Posted Date
- 2025-03-25
- Last Posted Date
- 2025-03-30
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06828588
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer
Early Phase 1
Recruiting
- Conditions
- HNSCCHNSCC,Larynx, Pharynx and Oral Cavity
- Interventions
- First Posted Date
- 2025-02-11
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06819228
- Locations
- 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
The Clonal Hematopoiesis & Inflammation in Vasculature Registry and Biorepository
Recruiting
- Conditions
- Clonal Hematopoiesis
- First Posted Date
- 2024-11-22
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 800
- Registration Number
- NCT06701214
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Biomarker Platform (Virtual Nodule Clinic) for the Management of Indeterminate Pulmonary Nodules
Not Applicable
Recruiting
- Conditions
- Lung Neoplasm
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2025-06-24
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 400
- Registration Number
- NCT06638398
- Locations
- 🇺🇸
University of Colorado, Aurora, Colorado, United States
🇺🇸Washington University in St. Louis, Saint Louis, Missouri, United States
🇺🇸Meharry Medical College, Nashville, Tennessee, United States
Cryodevitalization for the Treatment of Early Stage Lung Cancer, CRYSTAL Trial
Not Applicable
Recruiting
- Conditions
- Stage I Lung CancerStage II Lung Cancer
- Interventions
- Procedure: CryosurgeryProcedure: Robotic BronchoscopyProcedure: Bronchoscopy with BiopsyProcedure: ResectionProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Biospecimen CollectionOther: Electronic Health Record Review
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2024-11-08
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT06593106
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Cohort to Augment the Understanding of Sarcoma Survivorship Across the Lifespan
Recruiting
- Conditions
- Sarcoma
- Interventions
- Other: SurveysOther: Blood CollectionOther: Saliva CollectionOther: Urine CollectionOther: Stool CollectionOther: Tissue collectionOther: Physical Activity Monitoring
- First Posted Date
- 2024-07-01
- Last Posted Date
- 2024-07-01
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 2100
- Registration Number
- NCT06482957
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Eltanexor and Venetoclax in Relapsed or Refractory Myelodysplastic Syndrome and Acute Myeloid Leukemia
Phase 1
Recruiting
- Conditions
- Relapsed Myelodysplastic SyndromeRefractory Myelodysplastic SyndromeAcute Myeloid LeukemiaRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
- Interventions
- Procedure: Bone Marrow Aspiration and BiopsyProcedure: Biospecimen Collection
- First Posted Date
- 2024-05-06
- Last Posted Date
- 2025-03-27
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06399640
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer
Phase 2
Terminated
- Conditions
- Stage I Lung CancerStage II Lung CancerLimited Stage Lung Small Cell CarcinomaStage III Lung Cancer
- Interventions
- Procedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Magnetic Resonance ImagingProcedure: Biospecimen CollectionRadiation: Radiation Therapy
- First Posted Date
- 2023-11-20
- Last Posted Date
- 2025-06-05
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT06140407
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation
Phase 1
Recruiting
- Conditions
- Stage IV Lung CancerExtensive Stage Lung Small Cell Carcinoma
- Interventions
- Biological: AtezolizumabRadiation: Total Body IrradiationRadiation: Hypofractionated Radiation TherapyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2023-10-31
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 18
- Registration Number
- NCT06110572
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States